...
首页> 外文期刊>Microbial Cell Factories >Combinatorial engineering of hybrid mevalonate pathways in Escherichia coli for protoilludene production
【24h】

Combinatorial engineering of hybrid mevalonate pathways in Escherichia coli for protoilludene production

机译:大肠杆菌中合成甲羟戊酸途径的组合工程用于生产原孕二烯

获取原文
           

摘要

Protoilludene is a valuable sesquiterpene and serves as a precursor for several medicinal compounds and antimicrobial chemicals. It can be synthesized by heterologous expression of protoilludene synthase in Escherichia coli with overexpression of mevalonate (MVA) or methylerythritol-phosphate (MEP) pathway, and farnesyl diphosphate (FPP) synthase. Here, we present E. coli as a cell factory for protoilludene production. Protoilludene was successfully produced in E. coli by overexpression of a hybrid exogenous MVA pathway, endogenous FPP synthase (IspA), and protoilludene synthase (OMP7) of Omphalotus olearius. For improving protoilludene production, the MVA pathway was engineered to increase synthesis of building blocks isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) by sequential order permutation of the lower MVA portion (MvL), the alteration of promoters and copy numbers for the upper MVA portion (MvU), and the coordination of both portions, resulting in an efficient entire MVA pathway. To reduce the accumulation of mevalonate observed in the culture broth due to lower efficiency of the MvL than the MvU, the MvL was further engineered by homolog substitution with the corresponding genes from Staphylococcus aureus. Finally, the highest protoilludene production of 1199?mg/L was obtained from recombinant E. coli harboring the optimized hybrid MVA pathway in a test tube culture. This is the first report of microbial synthesis of protoilludene by using an engineered E. coli strain. The protoilludene production was increased by approx. Thousandfold from an initial titer of 1.14?mg/L. The strategies of both the sequential order permutation and homolog substitution could provide a new perspective of engineering MVA pathway, and be applied to optimization of other metabolic pathways.
机译:原硅二烯是有价值的倍半萜烯,并且用作几种药物化合物和抗微生物化学品的前体。它可以通过在大肠杆菌中异戊二烯合酶的异源表达,甲羟戊酸(MVA)或甲基赤藓糖醇磷酸(MEP)途径和法呢基二磷酸(FPP)合酶的过表达来合成。在这里,我们介绍了大肠杆菌作为生产原孕二烯的细胞工厂。通过过量表达油橄榄Omphalotus的杂种外源性MVA途径,内源性FPP合酶(IspA)和原戊二烯合酶(OMP7),在大肠杆菌中成功生产了原孕二烯。为了提高原戊二烯的产量,对MVA途径进行了工程改造,以通过下部MVA部分(MvL)的顺序排列置换,启动子和上部拷贝数的改变来增加结构单元异戊烯二磷酸(IPP)和二甲基烯丙基二磷酸(DMAPP)的合成MVA部分(MvU),以及这两个部分的协调,形成了有效的完整MVA途径。为了减少由于MvL的效率低​​于MvU而导致的在肉汤中观察到的甲羟戊酸的积累,通过用金黄色葡萄球菌的相应基因进行同源替换进一步改造了MvL。最后,在试管培养中,从具有最佳杂交MVA途径的重组大肠杆菌中获得最高的原戊二烯生产量1199?mg / L。这是通过使用工程化的大肠杆菌菌株微生物合成原孕二烯的首次报道。原硅二烯的产量增加了约。初始滴度为1.14?mg / L的数千倍。顺序置换和同源替换的策略可以为工程MVA途径的研究提供新的视角,并应用于其他代谢途径的优化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号